414 related articles for article (PubMed ID: 11429666)
1. Infliximab for the treatment of Crohn's disease: review and indications for clinical use in Canada.
Panaccione R;
Can J Gastroenterol; 2001 Jun; 15(6):371-5. PubMed ID: 11429666
[TBL] [Abstract][Full Text] [Related]
2. Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics.
Feagan BG; Enns R; Fedorak RN; Panaccione R; Paré P; Steinhart AH; Wild G
Can J Clin Pharmacol; 2001; 8(4):188-98. PubMed ID: 11743591
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate for induction of remission in refractory Crohn's disease.
McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
[TBL] [Abstract][Full Text] [Related]
4. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
Keating GM; Perry CM
BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
[TBL] [Abstract][Full Text] [Related]
5. Transcending conventional therapies: the role of biologic and other novel therapies.
Sandborn WJ
Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions.
Kinney T; Rawlins M; Kozarek R; France R; Patterson D
Am J Gastroenterol; 2003 Mar; 98(3):608-12. PubMed ID: 12650795
[TBL] [Abstract][Full Text] [Related]
7. Maintenance of remission in Crohn's disease: current and emerging therapeutic options.
Brookes MJ; Green JR
Drugs; 2004; 64(10):1069-89. PubMed ID: 15139787
[TBL] [Abstract][Full Text] [Related]
8. Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study.
Schröder O; Blumenstein I; Stein J
Eur J Gastroenterol Hepatol; 2006 Jan; 18(1):11-6. PubMed ID: 16357613
[TBL] [Abstract][Full Text] [Related]
9. Infliximab in treatment of Crohn's disease: the Milan experience.
Ardizzone S; Colombo E; Maconi G; Bollani S; Manzionna G; Petrone MC; Bianchi Porro G
Dig Liver Dis; 2002 Jun; 34(6):411-8. PubMed ID: 12132788
[TBL] [Abstract][Full Text] [Related]
10. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
Sandborn WJ; Hanauer SB
Am J Gastroenterol; 2002 Dec; 97(12):2962-72. PubMed ID: 12492177
[TBL] [Abstract][Full Text] [Related]
11. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
[TBL] [Abstract][Full Text] [Related]
12. Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine.
Schröder O; Blumenstein I; Schulte-Bockholt A; Stein J
Aliment Pharmacol Ther; 2004 Feb; 19(3):295-301. PubMed ID: 14984376
[TBL] [Abstract][Full Text] [Related]
13. [Indications and results of infliximab in Crohn's disease].
Karoui S; Boubaker J; Filali A
Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
[TBL] [Abstract][Full Text] [Related]
14. Approach to corticosteroid-dependent and corticosteroid-refractory Crohn's disease.
Lichtenstein GR
Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S23-9. PubMed ID: 11380040
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
16. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S
Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301
[TBL] [Abstract][Full Text] [Related]
18. [Infliximab in the treatment of patients with Crohn's disease: preliminary report].
Gellona V J; Zarraonandia A A; Zúñiga D A; Palma C R; Contreras P J; Silva Ch J; González D R; Quintana V C
Rev Med Chil; 2006 Mar; 134(3):320-5. PubMed ID: 16676104
[TBL] [Abstract][Full Text] [Related]
19. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
20. Mild to moderate Crohn's disease: still room for step-up therapies?
Bar-Meir S
Dig Dis; 2009; 27(3):347-50. PubMed ID: 19786763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
